The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
T-cells targeted with anti-CD3 x anti-HER2 bispecific antibody for treatment of women with stage IV breast cancer (phase I): Clinical and immune function results.
L. G. Lum
Stock Ownership - TransTarget
R. Rathore
No relevant relationships to disclose
Z. Al-Kadhimi
No relevant relationships to disclose
P. Davol
No relevant relationships to disclose
A. Thakur
No relevant relationships to disclose
C. Pray
No relevant relationships to disclose
Q. Liu
No relevant relationships to disclose
E. Tomaszewski
No relevant relationships to disclose
F. Cummings
No relevant relationships to disclose
P. Steele
No relevant relationships to disclose
J. Wedge
No relevant relationships to disclose
N. Kouttab
No relevant relationships to disclose
A. Maizel
No relevant relationships to disclose
W. Colaiace
No relevant relationships to disclose
R. Joyrich
No relevant relationships to disclose
V. Ratanatharathorn
No relevant relationships to disclose
J. P. Uberti
No relevant relationships to disclose